A small Memorial Sloan Kettering Cancer Center study found that all rectal cancer patients treated with GSK drug Jemperli showed a complete response at six months—there were no detectable signs of the cancer. These early data presented at ASCO suggest that rectal cancer with a particular genetic signature might be treatable with this immunotherapy in lieu of the standard regimen of chemotherapy, radiation, and surgery.

Recent efforts to improve transparency haven’t made much of a difference, one author noted. But earlier reforms made a dent the “most egregious” practices.

A federal jury in California found that Kite Pharma – now part of Gilead Sciences – violated a patent from Memorial Sloan Kettering Cancer Center and licensed to BMS’ Juno Therapeutics in developing the CAR-T therapy Yescarta, approved in 2017.

Memorial Sloan Kettering Chief Medical Officer Jose Baselga resigned Thursday following publication of a New York Times-ProPublica investigation of his financial relationships with drugmakers.

Memorial Sloan Kettering’s Dr. Jose Baselga, a top breast cancer doctor, omitted relationships from journal articles, including more than $3 million in payments from Roche, The New York Times and ProPublica reported.

Mouse model study uses PD-1 antibody technology from Eureka Therapeutics, which is also developing T-cell receptor therapies.

The two New York City-based organizations have partnered on an initiative aimed at precision oncology research and treatment. By leveraging Cota’s classification system, Memorial Sloan Kettering will improve patient care and accelerate research efforts.

As part of a new research collaboration, Memorial Sloan Kettering Cancer Center and Philips will be using DNA sequencing technologies to better understand pancreatic cancer.

“There is a real need to detect cancers that are small [less than 1 cm] before they metastasize. That would be the Holy Grail.”